

ALMIRALL, S.A.
2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS
REPORT OF THE BOARD OF DIRECTORS ON THE PROPOSAL FOR THE
APPOINTMENT OF MS. IVANA MAGOVČEVIĆ-LIEBISCH AS AN INDEPENDENT
DIRECTOR

1. INTRODUCTION

This report has been prepared by the Board of Directors of Almirall, S.A. (the “**Company**” or “**Almirall**”) in accordance with the provisions of section 529.5 *decies* of the consolidated version of the Spanish Companies Act, approved by Royal Legislative Decree 1/2010, of 2 July (the “**Spanish Companies Act**”), in order to report favourably on the proposed appointment of Ms. Ivana Magovčević-Liebisch as an independent director of the Company, to be submitted for approval at the next Annual General Meeting of the Company.

In accordance with the provisions of section 529.5 *decies* of the Spanish Companies Act, the Board of Directors of Almirall has considered the skills, experience and merits of Ms. Ivana Magovčević-Liebisch, based on a substantiated proposal prepared by the Nominations and Remuneration Commission under section 529.4 *decies* of the Spanish Companies Act. The proposal by the Nominations and Remuneration Commission is attached as **Annex I** to this report.

2. ASSESSMENT OF THE CANDIDATE

The following is the Board of Directors’ assessment of the competence, professional experience and merits of Ms. Ivana Magovčević-Liebisch, and her suitability to discharge her duties as an independent director of the Company in view of the proposal made by the Company’s Nominations and Remuneration Commission at its meeting of 6 April 2026, under section 529.4 *decies* of the Spanish Companies Act.

In accordance with section 518.e) of the Spanish Companies Act, this report includes complete information on the identity, curriculum and category of the proposed Director, as well as an assessment of whether the Director meets the suitability requirements for the performance of the duties of an independent director of the Company.

2.1 PROFESSIONAL AND BIOGRAPHICAL PROFILE

Ms. Ivana Magovčević-Liebisch has over 25 years of experience in senior management positions. Ms. Magovčević-Liebisch currently serves as President and Chief Executive Officer of Draig Therapeutics Ltd. (Cardiff, Wales), a clinical-stage company focused on neuropsychiatric diseases. Previously, she founded and led Vigil Neuroscience, serving as President and Chief Executive Officer from its inception until its acquisition by Sanofi in August 2025, leading the company through its evolution from an early-stage company with preclinical assets to a clinical-stage organisation following its initial public offering.

Prior to that, Ms. Magovčević-Liebisch served as Executive Vice President and Chief Business Officer at Ipsen, where she led the development of the company’s project portfolio through the

execution of key strategic transactions. Before that, she held the position of Senior Vice President and Head of Global Business Development at Teva Pharmaceutical. Previously, between 2001 and 2013, she developed her career at Dyax, where she held, among other positions, the roles of Executive Vice President, Chief Operating Officer, Chief Business Officer and General Counsel.

Ms. Magovčević-Liebisch currently serves on the Boards of Directors, as an independent director, of Acrivon Therapeutics and Quanterix Corporation. Ms. Magovčević-Liebisch is also actively involved in the non-profit sector, where she serves as a Trustee of the Museum of Science (Boston) and the Boston Ballet, and as a member of the supervisory board of Beth Israel Deaconess Medical Center.

Ms. Magovčević-Liebisch holds a Doctorate in Genetics from Harvard University and obtained a Juris Doctor (JD) degree in High Technology Law from Suffolk University Law School. She graduated summa cum laude with a Bachelor's degree in Biology and Chemistry from Wheaton College.

2.2 VALIDATION

The Board of Directors endorses the proposal of the Nominations and Remuneration Commission and considers that the curriculum vitae and professional profile of Ms. Ivana Magovčević-Liebisch are evidence that the candidate has the appropriate skills, professional experience and merits to be appointed as an independent director of the Company by the next General Shareholders' Meeting, and that she is not subject to any grounds of incompatibility, prohibition or conflict of interest.

2.3 CATEGORY

Ms. Ivana Magovčević-Liebisch has been proposed by the Nominations and Remuneration Commission in view of her personal and professional qualities. The Nominations and Remuneration Commission has verified that she is not subject to any of the prohibitions set out in section 529.4 *duodecies* of the Spanish Companies Act and believes that she may hold the position without being conditioned by any relationship with the Company or its group, its significant shareholders or Directors. Therefore, the candidate fulfils the requirements to be classified as an independent director of the Company under applicable regulations.

3. FAVOURABLE OPINION

Based on the information provided, it appears that Ms. Ivana Magovčević-Liebisch has the necessary skills, professional experience and merits to discharge the duties of the office of an independent director. Therefore, the Board of Directors hereby issues a favourable opinion on the appointment of Ms. Ivana Magovčević-Liebisch at the next Annual General Meeting as an independent director of the Company for the term of two years, following the substantiated proposal submitted by the Nominations and Remuneration Commission.

In Barcelona, 6 April 2026.

ANNEX I
PROPOSAL OF THE NOMINATIONS AND REMUNERATION COMMISSION OF
ALMIRALL, S.A. IN RELATION TO THE APPOINTMENT OF MS. IVANA
MAGOVČEVIĆ-LIEBISCH AS AN INDEPENDENT DIRECTOR

1. INTRODUCTION

This report has been prepared by the Nominations and Remuneration Commission of Almirall, S.A. (the “**Company**” or “**Almirall**”) under section 529.4 *decies* of the consolidated version of the Spanish Companies Act, approved by Royal Decree-Law 1/2010, of 2 July (the “**Spanish Companies Act**”). It is intended to provide the Board of Directors with a substantiated proposal regarding the appointment of Ms. Ivana Magovčević-Liebisch as an independent Director, to be submitted to the shareholders of the Company for approval at the next Annual General Meeting.

The Nominations and Remuneration Commission has reviewed the current composition of the Board of Directors and, after examining the matrix of responsibilities of the Board of Directors and its current competencies and needs, has concluded that it is necessary appoint a new independent director with experience and background in the pharmaceutical sector.

To this end, a search has been carried out for the best candidates to be appointed as members of the Board of Directors. Following the relevant analyses and interviews, the Nominations and Remuneration Commission has resolved to submit the proposal for the appointment of Ms. Ivana Magovčević-Liebisch as an independent director to the Board of Directors for subsequent approval by the General Meeting of Shareholders.

2. PROPOSED APPOINTMENT

2.1 PROFESSIONAL AND BIOGRAPHICAL PROFILE

Ms. Ivana Magovčević-Liebisch has over 25 years of experience in senior management positions. Ms. Magovčević-Liebisch currently serves as President and Chief Executive Officer of Draig Therapeutics Ltd. (Cardiff, Wales), a clinical-stage company focused on neuropsychiatric diseases. Previously, she founded and led Vigil Neuroscience, serving as President and Chief Executive Officer from its inception until its acquisition by Sanofi in August 2025, leading the company through its evolution from an early-stage company with preclinical assets to a clinical-stage organisation following its initial public offering.

Prior to that, Ms. Magovčević-Liebisch served as Executive Vice President and Chief Business Officer at Ipsen, where she led the development of the company’s project portfolio through the execution of key strategic transactions. Before that, she held the position of Senior Vice President and Head of Global Business Development at Teva Pharmaceutical. Previously, between 2001 and 2013, she developed her career at Dyax, where she held, among other positions, the roles of Executive Vice President, Chief Operating Officer, Chief Business Officer and General Counsel.

Ms. Magovčević-Liebisch currently serves on the Boards of Directors, as an independent director, of Acrivon Therapeutics and Quanterix Corporation. Ms. Magovčević-Liebisch is also actively involved in the non-profit sector, where she serves as a Trustee of the Museum of

Science (Boston) and the Boston Ballet, and as a member of the supervisory board of Beth Israel Deaconess Medical Center.

Ms. Magovčević-Liebisch holds a Doctorate in Genetics from Harvard University and obtained a Juris Doctor (JD) degree in High Technology Law from Suffolk University Law School. She graduated summa cum laude with a Bachelor's degree in Biology and Chemistry from Wheaton College.

2.2 CATEGORY

Ms. Ivana Magovčević-Liebisch has been proposed by the Nominations and Remuneration Commission in view of her personal and professional qualities. The Nominations and Remuneration Commission has verified that she is not subject to any of the prohibitions set out in section 529.4 *duodecies* of the Spanish Companies Act and believes that she may hold the position without being conditioned by any relationship with the Company or its group, its significant shareholders or Directors. Therefore, Nominations and Remuneration Commission concludes that Ms. Ivana Magovčević-Liebisch fulfils the requirements to be classified as an independent director of the Company.

3. PROPOSED RESOLUTION

In view of the foregoing, the Nominations and Remuneration Commission considers that Ms. Ivana Magovčević-Liebisch has the appropriate competence, experience and merits to perform her duties as a director of the Company under the conditions established by law and therefore submits to the Board of Directors the proposal to appoint Ms. Ivana Magovčević-Liebisch as a director of the Company, with the category of independent Director, for the term of two years.

The full text of the proposed resolution is as follows:

"NINTH 5.- Item 9.5 of the Agenda

Appointment of Ms. Ivana Magovčević-Liebisch as independent Director.

In accordance with the proposal of the Nominations and Remuneration Commission and the report of the Board of Directors, to appoint Ms. Ivana Magovčević-Liebisch, of legal age, of United States nationality, with address at Ronda del General Mitre, 151, 08022 Barcelona and a holder of a passport of her nationality number 567580982, as a member of the Board of Directors and specifically as an independent Director for the statutory term of 2 years from the date of her appointment by the General Shareholders' Meeting.

The proposed appointment is supported by a report of the Board of Directors assessing the competence, professional experience and merits of Ms. Ivana Magovčević-Liebisch. This report and the above proposal submitted by the Nominations and Remuneration Commission have been made available to the shareholders since the publication of the notice convening the General Shareholders' Meeting.

Ms. Ivana Magovčević-Liebisch may accept her appointment in any manner permitted by law."

In Barcelona, 6 April 2026.